HK Stock Market Move | Innovative drug concept stocks rose in early trading, and the "Medical Spring Festival Gala" JPM conference officially kicked off. Chinese innovative pharmaceutical companies will collectively make appearances.

Concept stocks of innovative drugs rose in the morning session, as of the submission, 3SBIO (01530) rose by 6.35% to 28.82 Hong Kong dollars; WuXi AppTec (02359) rose by 7.22% to 118.8 Hong Kong dollars; LEPU BIO-B (02157) rose by 6.64% to 28.9 Hong Kong dollars; ASCLETIS-B (01672) rose by 4.09% to 12.97 Hong Kong dollars; EVEREST MED (01952) rose by 3.97% to 40.84 Hong Kong dollars. On the news front, on January 12, 2026 local time, the 44th Annual JPMorgan Healthcare Conference officially kicked off in San Francisco. It is reported that several Chinese innovative drug companies have confirmed their participation so far. The main speakers at the conference include WuXi AppTec, WUXI BIO, WUXI XDC3 CXO companies, as well as BEONE MEDICINES, ZAI LAB, ASHIN BIO, and Legend Biotech, among others. Seventeen companies including Jiangsu Hengrui Pharmaceuticals, Sichuan Biokin Pharmaceutical, 3SBIO, and REMEGEN will participate in the Asia-Pacific session. Sinolink believes that this conference is a key platform for domestic drug companies to showcase their core molecular product capabilities and promote overseas BD cooperation. With the normalization of BD, the industry is returning to the stage of global product value validation. With the advancement of global clinical trials, the release of major data, and the optimization of the competitive landscape, the global value of products and the valuation of companies will undergo multiple rounds of reassessment. Hua Yuan Securities stated that China Meheco Group's industry has essentially completed the transition from old to new growth engines, with innovative drugs significantly opening up new growth curves for companies.